Clinic
Providence Hospital
Providence Hospital was paid $4.87M by Medicaid between Jan 2018 and Feb 2024, across 74 billing codes. Its largest line is 99285, emergency room visit (most serious) — 37% of everything it billed.
33Billing provider infoPROVIDENCE HOSPITAL
MOBILE, AL 36608
MOBILE, AL 36608
33aNPI1952390643assigned 10/17/2005
33bProvider typeLithotripsy Clinic/Center
28Total paid$4.87M
24GClaims155,500
24DCodes billed74
24AFirst – last monthJan 2018 – Feb 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,450 | $1.00M | |
| 2019 | 32,634 | $916K | |
| 2020 | 15,146 | $504K | |
| 2021 | 18,752 | $594K | |
| 2022 | 21,183 | $768K | |
| 2023 | 25,421 | $1.04M | |
| 2024incomplete | 914 | $40K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 37% | 8,479 | 6,832 | $1.80M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 20,837 | 17,319 | $1.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 23,882 | 20,268 | $882K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 20,161 | 16,449 | $148K |
| 80053 | Comprehensive metabolic panel | 3.0% | 15,739 | 12,919 | $145K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.3% | 1,841 | 1,576 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,168 | 1,123 | $54K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 331 | 149 | $53K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 883 | 635 | $51K |
| 87449 | 1.1% | 3,984 | 3,436 | $51K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 901 | 692 | $40K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,033 | 732 | $37K |
62 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,805 | $32K |
| 81001 | <1% | 8,024 | $27K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,228 | $21K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,536 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,239 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 993 | $16K |
| 87070 | <1% | 1,586 | $16K | |
| 87634 | <1% | 360 | $14K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 564 | $13K |
| 62322 | <1% | 73 | $9K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 395 | $9K |
| D9420 | <1% | 30 | $9K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 44 | $9K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,289 | $7K |
| 84484 | <1% | 938 | $7K | |
| 82553 | <1% | 628 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 812 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,196 | $4K |
| 86756 | <1% | 238 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 30 | $4K |
| 87430 | <1% | 262 | $3K | |
| 83735 | <1% | 689 | $3K | |
| 81025 | <1% | 1,144 | $3K | |
| 84702 | <1% | 247 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $2K |
| 87088 | <1% | 310 | $2K | |
| 82550 | <1% | 453 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 64 | $2K |
| 83690 | <1% | 394 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 115 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,499 | $2K |
| 88307 | <1% | 49 | $1K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 35 | $1K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 37 | $991.07 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 559 | $982.61 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 843 | $774.46 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,209 | $634.74 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 184 | $501.64 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,385 | $399.44 |
| 83880 | <1% | 16 | $391.44 | |
| 82247 | <1% | 122 | $316.40 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 85 | $283.08 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 177 | $247.04 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 196 | $182.41 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 99 | $181.68 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 109 | $122.73 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,801 | $115.76 |
| 87081 | <1% | 12 | $114.36 | |
| 85027 | <1% | 42 | $112.77 | |
| 85610 | <1% | 35 | $96.72 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 153 | $86.74 |
| 84703 | <1% | 22 | $67.40 | |
| G0378 | Hospital observation service, per hour | <1% | 35 | $51.32 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 34 | $51.05 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 31 | $20.79 |
| J2704 | Injection, propofol, 10 mg | <1% | 243 | $12.10 |
| 87077 | <1% | 12 | $8.98 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 17 | $6.10 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 112 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 196 | $0.00 |
| A9270 | Non-covered item or service | 0% | 196 | $0.00 |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKENNEDY, TODD (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Alabama Providence Healthcare Services | Mobile, AL | $4.75M |
| Providence Hospital | Mobile, AL | $647K |
| Providence Hospital | Mobile, AL | $37K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.